Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Depreciation & Amortization (CF): 2023-2025

Historic Depreciation & Amortization (CF) for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $461,000.

  • Tonix Pharmaceuticals Holding's Depreciation & Amortization (CF) fell 9.61% to $461,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 53.82%. This contributed to the annual value of $3.4 million for FY2024, which is 20.27% down from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Depreciation & Amortization (CF) stood at $461,000 for Q3 2025, which was down 4.55% from $483,000 recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Depreciation & Amortization (CF) high stood at $1.3 million for Q4 2023, and its period low was $461,000 during Q3 2025.
  • In the last 3 years, Tonix Pharmaceuticals Holding's Depreciation & Amortization (CF) had a median value of $893,000 in 2023 and averaged $829,818.
  • Within the past 5 years, the most significant YoY rise in Tonix Pharmaceuticals Holding's Depreciation & Amortization (CF) was 35.50% (2024), while the steepest drop was 60.67% (2024).
  • Quarterly analysis of 3 years shows Tonix Pharmaceuticals Holding's Depreciation & Amortization (CF) stood at $1.3 million in 2023, then slumped by 60.67% to $496,000 in 2024, then declined by 9.61% to $461,000 in 2025.
  • Its last three reported values are $461,000 in Q3 2025, $483,000 for Q2 2025, and $493,000 during Q1 2025.